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Abstract
Background: Breast cancer is the most common cancer and the leading cause of cancer mortality in women
worldwide. Hypoxia is an important factor involved in the progression of solid tumors and has been associated
with various indicators of tumor metabolism, angiogenesis and metastasis. But little is known about the
contribution of Hypoxia-Inducible Factor-2a (HIF-2a) to the drug resistance and the clinicopathological
characteristics in breast cancer.
Methods: Immunohistochemistry was employed on the tissue microarray paraffin sections of surgically removed
samples from 196 invasive breast cancer patients with clinicopathological data. The correlations between the
expression of HIF-2a and ABCG2 as well as other patients’ clinicopathological data were investigated.
Results: The results showed that HIF-2a was expressed in different intensities and distributions in the tumor cells
of the breast invasive ductal carcinoma. A positive staining for HIF-2a was defined as a brown staining observed
mainly in the nucleus. A statistically significant correlation was demonstrated between HIF-2a expression and
ABCG2 expression (p = 0.001), histology-grade (p = 0.029), and Ki67 (p = 0. 043) respectively.
Conclusion: HIF-2a was correlated with ABCG2 expression, histology-grade and Ki67 expression in breast invasive
ductal carcinoma. HIF-2a could regulate ABCG2 in breast cancer cells, and could be a novel potential bio-marker to
predict chemotherapy effectiveness. The hypoxia/HIF-2a/ABCG2 pathway could be a new mechanism of breast
cancer multidrug-resistance.
Virtual slides: http://www.diagnosticpathology.diagnomx.eu/vs/2965948166714795
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Background
Breast cancer is the most commonly diagnosed cancer
and the leading cause of cancer mortality in women
worldwide. Clinically, breast cancer is a remarkably het-
erogeneous disease in terms of gene expression, mor-
phology, clinical course, and response to treatment.
Traditionally, pathologic determinations of tumor size,
lymph node status, endocrine receptor status, and
human epidermal growth factor receptor 2 (HER2) sta-
tus have driven prognostic predictions and, ultimately,
adjuvant therapy recommendations for patients with
early stage breast cancer. In recent years, many potential
new prognostic markers of a biochemical nature have
been described for breast cancer. These include steroid-
hormone receptors, growth factor receptors, activated
proto-oncogenes, and proteolytic enzymes et al.
Hypoxia is an important factor involved in the pro-
gression of solid tumors and has been associated with
various indicators of tumor metabolism, angiogenesis
and metastasis [1]. The presence of widespread hypoxia
within tumors has been associated with reduced survival
after radiotherapy or chemotherapy. Hypoxia has also
been linked to poor outcome in a number of tumors
regardless of the treatment modalities used. Karolina
Helczynska et al. [2] found a significant association
between Hypoxia-Inducible Factor-2a (HIF-2a) protein
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and adverse prognosis of breast cancer, and no such
association was found for Hypoxia-Inducible Factor-1a.
In other words, HIF-2a is a possible potential indepen-
dent prognostic bio-marker of breast cancer.
ABCG2 (ATP-binding cassette sub-family G member
2), or breast cancer resistance protein (BCRP), is an vital
trans-membrane transporter which plays an important
role in the multidrug resistance (MDR) of breast cancer.
Recently, our research team found that ABCG2 is
associated with HER-2 expression, lymph node metasta-
sis and clinical stage in breast invasive ductal carcinoma
using immunohistochemistry (IHC) stain on the tissue
microarray paraffin sections of surgically removed sam-
ples from 196 breast cancer patients with clinicopatho-
logical data, which means ABCG2 may be a novel
potential prognostic bio-marker which can predict biolo-
gical behavior, clinical progression, prognosis and che-
motherapy effectiveness [3].
Two functional elements in the ABCG2 promoter, the
estrogen [4] and hypoxia [5] response elements (HRE),
and a peroxisome proliferator- activated receptor g
(PPARg) response element upstream of the ABCG2 gene
[6] have been shown to control ABCG2 expression. So, it
is interesting to explore the expression of these two
potential prognostic bio-markers, HIF-2a and ABCG2,
and their possible correlations in primary breast cancer.
In the present study, the expression of HIF-2a and
ABCG2 was detected by immunohistochemistry using
tissue microarray according to immunohistochemical
phenotypes and the correlationships between HIF-2a
and ABCG2 expression/the clinicopathological data
were discussed. We demonstrated a possibility of predic-
tive role of HIF-2a in chemotherapy of breast cancer.
Materials and methods
Patients and tissue samples
We retrieved tissue samples from patients with breast
invasive ductal carcinoma in the Department of Pathol-
ogy of Qilu Hospital of Shandong University during July
2007 through December 2008. Formalin-fixed and paraf-
fin-embedded tissue specimens from 196 patients with
primary breast cancer were included. All archival hema-
toxylin and eosin (H&E)-stained slides for each patient
were reviewed by two pathologists. For the usage of the
clinical materials for research purposes, prior patient
content and approval from the Institutional Research
Ethics Committee were obtained. All the diagnoses were
made following the Pathology and Genetics of Tumors
of Breast of the World Health Organization Classifica-
tion of Tumors [7]. Clinicopathologic classification and
staging were determined according to the American
Joint Committee on Cancer criteria [8].
The histological grade was assessed using the Notting-
ham grading system [9], and nuclear grade was
evaluated according to the modified Black’s nuclear
grade [10]. Histological parameters such as histological
subtype, nuclear grade and histological grade were eval-
uated according to H&E-stained slides. Clinical para-
meters included patients’ age, tumor size, lymph node
status, clinical stage and biological markers (ER, PR,
HER2 and ki67 et al.).
Tissue microarray
For each H&E-stained slide, two representative areas
were selected and the corresponding spots were marked
on the surface of the paraffin block. Using a tissue
microarray punching instrument, the selected areas were
punched out and were placed into the recipient block
side by side. Each tissue core was 2 mm in diameter and
was assigned with a unique tissue microarray location
number that was linked to a database containing other
clinicopathologic data.
Immunohistochemistry (IHC)
The streptavidin-peroxidase-biotin (SP) immunohisto-
chemical method was utilized to study the expression of
HIF-2a and ABCG2 in 196 paraffin-embedded breast
tissues.
In brief, paraffin-embedded specimens were cut into 4
μm sections and baked at 60°C for 60 min. The sections
were deparaffinized with xylenes and rehydrated. Then
sections were submerged into EDTA antigenic retrieval
buffer in a pressure cooker for 10 min and then cooled
at room temperature for 20 min. The sections were
treated with 3% hydrogen peroxide in methanol to
quench the endogenous peroxidase activity, followed by
incubation with normal serum to block nonspecific
binding. Mouse monoclonal HIF-2 alpha antibody
[ep190b] (1:2000; Abcam company, ab8365, USA) and
Mouse monoclonal ABCG2 antibody [BXP-21] (1:50;
Abcam Company, ab3380, USA) were incubated with
the sections overnight at 4°C; the second antibody was
from an SP reagent kit (Zhongshan Biotechnology Com-
pany, Beijing, China). After washing, the tissue sections
were treated with biotinylated anti-mouse secondary
antibody, followed by further incubation with streptavi-
din-horseradish peroxidase complex for 20 mins. Stained
with diaminobenzidine (DAB), the sections were coun-
terstained with hematoxylin. For negative controls, the
anti-HIF-2a and anti-ABCG2 antibodies were replaced
with PBS.
Evaluation of immunohistochemical staining
The stained slides were reviewed and scored indepen-
dently by two observers blinded to the patients’ informa-
tion, and the scores were determined by combining the
proportion of positively stained tumor cells and the
intensity of staining. Tumor cell proportion was scored
Xiang et al. Diagnostic Pathology 2012, 7:32
http://www.diagnosticpathology.org/content/7/1/32
Page 2 of 6
as follows [11]: 0 (≤ 10% positive tumor cells); 1 (≤ 30%
positive tumor cells); 2 (31-50% positive tumor cells); 3
(51-80% positive tumor cells) and 4 (> 80% positive
tumor cells). Staining intensity was graded according to
the following criteria: 0 (-, no staining); 1 (+, weak stain-
ing = light yellow); 2 (++, moderate staining = yellow
brown) and 3 (+++, strong staining = brown). Staining
index (SI) was calculated as the product of the staining
intensity score and the proportion of positive tumor
cells. Using this method of assessment, we evaluated
HIF-2a and ABCG2 expression in invasive breast cancer
cells by determining the SI, with scores of 0,1, 2, 3, 4, 6,
9 or 12. The optimal cutoff value for high and low
expression level was identified: an SI score of ≥ 4 was
used to define tumors with high expression of HIF-2a
and ABCG2, and an SI score of ≤ 3 was used to indicate
low expression of HIF-2a and ABCG2, and the SI score
of 0 was used to imply negative expression, respectively.
Statistical analysis
The chi-square test or Fisher’s exact test were used to
evaluate the correlation between HIF-2a expression and
ABCG2 expression, as well as the clinicopathologic
characteristics if appropriate. Statistical Analyses were
performed using the statistical software package SPSS
13.0 (SPSS, Chicago, IL). Differences were considered
statistically significant for p < 0.05.
Results
The specificity of the immunodetection was confirmed
by using the monoclonal antibodies HIF-2a antibody
[ep190b]. A positive stain for HIF-2a was defined as a
brown stain observed mainly in the nucleus, and a nega-
tive or weak cytoplasmic reactivity observed. Positive
staining of normal adjacent ductal epithelia as well as
vascular endothelium and stromal cells of the breast has
a low level expression (Figure 1). And it can serve as an
internal positive control.
In the cells of the breast invasive ductal carcinoma,
HIF-2a expression was present in different intensities
and different cell distributions. Following the staging cri-
teria of stain intensity, 12 cases (6.12%) were identified
as completely negative (Figure 2), 78 cases (39.80%)
were identified as “+” (Figure 3), 69 cases (35.20%) were
identified as “++” (Figure 4), and 37 cases (18.88%) were
identified as “+++” (Figure 5). According to the above
assessment methods and evaluation criterion, combining
the proportion of positively stained tumor cells, the
negative, low level and high level expression of HIF-2a
was observed in 25 cases (12.76%), 114 cases (58.16%)
and 57 cases (29.08%), respectively.
The IHC expression and distribution of ABCG2 in
invasive breast cancer cells are as same as the findings
of our previous study [3].
There was no significant correlation between the
expression level of HIF-2a and biological factors such as
patients’ age (p = 0.053), histology type (p = 0.285),
tumour size (p = 0.601), lymph node metastasis (p =
0.808), ER (p = 0.544), PR (p = 0.343), HER-2 expression
(p = 0.923) and clinical stage (p = 0.538). In contrast,
statistical analyses indicated that HIF-2a expression was
positively related with ABCG2 expression and the corre-
lation was statistically significant (p = 0.001); meanwhile,
the correlation between HIF-2a expression and histol-
ogy-grade/Ki67 was significant (p = 0.029/0.043, respec-
tively). The results are summarized in Table 1.
Discussion
HIF-2a, also known as endothelial PAS domain protein
1 (EPAS1) or member of PAS superfamily 2 (MOP2)
Figure 1 Normal breast tissue, HIF-2a positive (IHC, SP × 200). The
HIF-2a staining is weak, and mainly localized mainly in the nucleus of
the glandular epithelium cells and vascular endothelium of the breast.
Figure 2 Breast cancer tissue, HIF-2a negative (IHC, SP × 200).
The HIF-2a staining is almost negative.
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[12-15], was the second HIF family member to be iden-
tified and belonged to the basic helix-loop-helix
(bHLH)/Per-ARNT-Sim (PAS) domain family of tran-
scription factors [16]. It activates gene expression via
formation of a dimeric complex with HIF-1b (also called
aryl hydrocarbon receptor nuclear translocator, ARNT)
and subsequent binding to hypoxia response elements
(HREs) within target genes. Among its transcription
Figure 3 Breast cancer tissue, HIF-2a positive + (IHC, SP × 200). The
HIF-2a staining is weak. Left top shows the normal duct of the breast.
Figure 4 Breast cancer tissue, HIF-2a positive ++ (IHC, SP ×
200). The HIF-2a staining is moderate.
Figure 5 Breast cancer tissue, HIF-2a positive +++ (IHC, SP ×
200). The HIF-2a staining is strong.
Table 1 The correlation between the expression of HIF-2
alpha and BCRP, the clinicopathological parameter





negative 26 8 17 1
low 97 12 58 27
high 73 5 39 29
Age 0.053
≤ 50 years 80 10 54 16
> 50 years 116 15 60 41
Histology-type 0.285
IDC 155 22 86 47
IDC with others 41 3 28 10
Histology-grade 0.029*
G1/G2 143 16 78 49
G3 53 9 36 8
Tumour size 0.601
≤2.0 cm 97 13 53 31
> 2.0 cm 99 12 61 26
LNM 0.808
- 103 13 58 32
+ 93 12 56 25
ER 0.544
-/+ 96 10 59 27
++/+++ 100 15 55 30
PR 0.343
-/+ 128 14 79 35
++/+++ 68 11 35 22
HER2 0.923
-/+ 138 18 81 39
++/+++ 58 7 33 18
Ki67 0.043*
Positive ≤50% 154 20 83 51
Positive > 50% 42 5 31 6
Clinical stage 0.538
Stage I 60 7 33 20
Stage IIa and IIb 86 13 47 26
StageIIIa and IIIb 50 5 34 11
P values were evaluated by chi-square test or the Fisher’s exact test. *P < 0.05
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targets are genes involved in proliferation, metabolism,
angiogenesis, differentiation, and metastasis [1]. Numer-
ous immunochemical analyses have demonstrated that
HIF-2a was over-expressed in a number of primary and
metastatic human cancers, and that the level of expres-
sion, either as a result of tumor hypoxia or genetic
alterations, is correlated with tumor angiogenesis and
patient mortality. High HIF-2a expression has been
linked to poor patient outcome in several tumor types
[17-21].
In the present study, we studied HIF-2a expression in
paraffin-embedded tumor samples using the IHC
method with the Abcam Mouse monoclonal HIF-2
alpha antibody [ep190b, ab8365], and the positive stain
for HIF-2a is located mainly in the nucleus of cells as
the product leaflet of the antibody indicates.
In our study, the expression HIF-2a of in most tumor
cells (87.24%) of the breast invasive ductal carcinoma is
positive, in which about 1/3 cases present relatively high
HIF-2a expression in the breast cancer cells. Further-
more, the expression of HIF-2a is correlated with the
histology-grade (p = 0.029) and the expression of Ki67
(p = 0.043). Those patients with high expression of HIF-
2a were demonstrated to be more frequently showing
high histology-grade and high expression of Ki67, which
means that HIF-2a have some correlation with worse
biological behavior and clinical aggressiveness.
To the best of our knowledge, this is the first report
that the expression of HIF-2a is correlated with histol-
ogy-grade and the expression of Ki67 in the cohort of
breast invasive ductual carcinoma. We think it is of
great importance for further research. In general, it is
consistent with previous literature that high expression
of HIF-2a have a worse prognosis than those with low
expression. Because there was no case in clinical IV
stage in the 196 patients which were used in the study,
it is impossible to evaluate the correlation between HIF-
2a expression and cases with distant metastasis.
In the study of Helczynska K et al. [2], the expression
of HIF-2a is located both in nucleus and cytoplasm of
the tumor cells by IHC detection and show a significant
correlation to incidence of distant recurrence. We think
the different antibodies and clinicopathologic variables
used in the two studies may contribute the different
results between the study of Helczynska K et al. and
ours.
ABCG2 (or BCRP), is the second member of the G
subfamily of the ATP-binding cassette (ABC) efflux
transporter superfamily that has been the subject of
intense study.
In our previous study [3], we found the expression of
ABCG2 protein correlated with Her-2 expression, lymph
node metastasis and clinical stage in breast invasive duc-
tal carcinoma and ABCG2 could be a novel potential
bio-marker which can predict biological behavior, clini-
cal progression, prognosis and chemotherapy
effectiveness.
In the present study, we found HIF-2a expression was
correlated with ABCG2 expression significantly (p =
0.001) in paraffin-embedded tumor samples using the
IHC method. It means that those patients with high
expression of HIF-2a were demonstrated to be more
frequently showing high immunoreactions with ABCG2,
which suggests that HIF-2a may have some correlation
with worse chemotherapy effectiveness. The finding is
consistent with the study of Cindy M. Martin et al. [22],
in whose report HIF-2a was found being a potent tran-
scriptional regulator of the Abcg2 gene, and HIF-2a
bond an evolutionary conserved HIF-2a response ele-
ment (HRE) in the murine Abcg2 promoter. A hypoth-
esis had been raised by Cindy M. Martin et al. that
Abcg2 is a direct downstream target of HIF-2a in the
side population (SP) progenitor cell population of the
adult heart. But in the area of cancer research, there is
no such kind of report. To the best of our knowledge,
this is the first report that the expression of HIF-2a is
correlated with ABCG2 expression in the cohort of
breast invasive ductual carcinoma. Our findings could
be another evidence for the above hypothesis. And in
the area of the mechanism research of breast cancer
MDR, our findings pointed out another possible genesis
mechanism that hypoxia could induce the expression of
ABCG2 by HIF-2a, which promoted the multidrug
resistance of breast cancer cells.
Because of the evaluation of IHC staining and samples
selecting of tissue microarray, some errors of our study
could be possible. Whether HIF-2a is correlated with
the prognosis of breast cancer and whether the above
possible regulation pathways is correct in cancer cells
need to be explored by further study.
Conclusion
Our study demonstrates the expression of HIF-2a in
normal ductal epithelia and in the tumor cells of inva-
sive ductal carcinoma of breast. Its expression is corre-
lated significantly with that of histology-grade and Ki67
in invasive ductal breast cancer. The study also found
HIF-2a expression was correlated with ABCG2 expres-
sion significantly, which suggests HIF-2a be a potent
transcriptional regulator of the Abcg2 gene and Abcg2
be a direct downstream target of HIF-2a in the cells of
invasive ductal breast cancer. These findings suggest
that HIF-2a is not only one of the hypoxia inducible
factors, but also a novel potential bio-marker which
could predict worse chemotherapy effectiveness in inva-
sive ductal carcinoma of breast; and indicate that
hypoxia promoted the multidrug resistance of breast
cancer cells by hypoxia/HIF-2a/ABCG2/MDR pathway.
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Further investigation on the molecular mechanism of
possible regulation relationships between them should
be done.
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